Saturday 17 October 2026
Export NMRA’s income statement to Excel — free account
Neumora Therapeutics, Inc.
NMRA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 30.3%, free cash flow grew 24.5% and total debt rose 172.0%, each against the same quarter a year earlier.
0.47
0.04
+9.30%
Follow NMRA
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
Current Ratio |
17.85 | 16.37 | 19.05 | 10.51 | 5.87 |
Net Debt/EBITDA |
5.17 | 2.70 | 1.78 | 1.15 | 0.53 |
Debt/Assets |
0.48% | 1.19% | 0.00% | 0.00% | 28.54% |
Debt/Equity |
0.01 | 0.01 | 0.00 | 0.00 | 0.53 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.32 | 0.88 | 0.69 | 0.75 | 0.87 |
Capex/Depreciation |
0.00 | 4.48 | 0.04 | 0.00 | (0.14) |
Interest Coverage |
— | (29.79) | — | — | (74.92) |
| 0.00% | 33.91% | (2,122.97%) | (64.48%) | (121.21%) | |
| 0.00% | (30.60%) | (51.15%) | (59.96%) | (93.28%) | |
ROIC |
0.00% | (283.30%) | (1,043.87%) | 0.00% | 0.00% |
Return on Tangible Assets |
(59.87%) | (35.70%) | (51.86%) | (85.45%) | (149.83%) |
Average Days of Receivables |
0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.50) | (4.24) | (2.51) | (1.15) | (1.26) |
Cash per Share |
2.69 | 13.67 | 6.98 | 1.94 | 1.12 |
Shareholders Equity per Share |
2.66 | 14.59 | 7.21 | 1.80 | 0.64 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.66 | 14.59 | 7.21 | 1.80 | 0.64 |
Free Cash Flow |
(75.42) | (115.41) | (163.39) | (182.94) | (206.22) |
Working Capital |
392.33 | 364.26 | 453.17 | 284.17 | 158.09 |
Capital Expenditures |
(0.82) | (0.51) | (0.12) | — | 0.22 |
Net Current Asset Value |
390.94 | 358.56 | 451.16 | 284.15 | 103.36 |
| Other line items | |||||
Quick Ratio |
17.59 | 15.70 | 18.08 | 10.33 | 5.62 |
Depreciation/Fixed assets |
0.38 | (0.05) | (1.72) | (4.46) | (37.92) |
Cash ROIC |
(9.24%) | (14.91%) | (17.70%) | (30.70%) | (60.49%) |
Accounts Receivable Turnover |
— | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | — | — | — |
Average Days of Payables |
385.71 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.50) | (4.22) | (2.51) | (1.15) | (1.26) |
Capex per Share |
0.00 | (0.02) | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.56 | — | — | — |
Average Payables |
— | 4.39 | 3.74 | 1.82 | 3.34 |
Average Assets |
— | 427.77 | 461.21 | 406.58 | 254.01 |
Average Common Equity |
— | (386.04) | 11.11 | 378.07 | 195.47 |
Capex to Sales |
— | 0.00 | 0.00 | — | 0.00 |
Columns are period end dates